StockData
Solid Biosciences Inc. logo

Solid Biosciences Inc. (SLDB) stock

SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$6.35+0.12 (+1.93%)

Close on Nov 18, 2026Market cap $680.88MP/E –Yield –

Solid Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Solid Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$212.15M. For fiscal 2025 it was -$179.21M. The highest annual figure on record is -$25.58M in fiscal 2016.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$179.21M–
FY2024Dec 31, 2024-$129.73M–
FY2023Dec 31, 2023-$104.25M–
FY2022Dec 31, 2022-$106.45M–
FY2021Dec 31, 2021-$72.25M–
FY2020Dec 31, 2020-$88.41M–
FY2019Dec 31, 2019-$119.32M–
FY2018Dec 31, 2018-$75.69M–
FY2017Dec 31, 2017-$54.86M–
FY2016Dec 31, 2016-$25.58M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$57.38M–
Q1 FY2026Mar 31, 2026-$57.31M–
Q4 FY2025Dec 31, 2025-$49.40M–
Q3 FY2025Sep 30, 2025-$48.06M–
Q2 FY2025Jun 30, 2025-$41.69M–
Q1 FY2025Mar 31, 2025-$40.05M–
Q4 FY2024Dec 31, 2024-$39.90M–
Q3 FY2024Sep 30, 2024-$35.18M–
Q2 FY2024Jun 30, 2024-$27.79M–
Q1 FY2024Mar 31, 2024-$26.86M–
Q4 FY2023Dec 31, 2023-$22.27M–
Q3 FY2023Sep 30, 2023-$23.11M–
Q2 FY2023Jun 30, 2023-$26.84M–
Q1 FY2023Mar 31, 2023-$32.03M–
Q4 FY2022Dec 31, 2022-$34.57M–
Q3 FY2022Sep 30, 2022-$21.13M–
Q2 FY2022Jun 30, 2022-$25.38M–
Q1 FY2022Mar 31, 2022-$25.37M–
Q4 FY2021Dec 31, 2021-$18.65M–
Q3 FY2021Sep 30, 2021-$18.03M–
Q2 FY2021Jun 30, 2021-$18.69M–
Q1 FY2021Mar 31, 2021-$16.89M–
Q4 FY2020Dec 31, 2020-$21.35M–
Q3 FY2020Sep 30, 2020-$21.23M–
Q2 FY2020Jun 30, 2020-$18.97M–
Q1 FY2020Mar 31, 2020-$26.86M–
Q4 FY2019Dec 31, 2019-$32.33M–
Q3 FY2019Sep 30, 2019-$29.72M–
Q2 FY2019Jun 30, 2019-$26.97M–
Q1 FY2019Mar 31, 2019-$30.30M–
Q4 FY2018Dec 31, 2018-$22.39M–
Q3 FY2018Sep 30, 2018-$19.15M–
Q2 FY2018Jun 30, 2018-$18.18M–
Q1 FY2018Mar 31, 2018-$15.97M–
Q4 FY2017Dec 31, 2017-$15.16M–
Q3 FY2017Sep 30, 2017-$13.70M–
Q2 FY2017Jun 30, 2017-$11.89M–
Q1 FY2017Mar 31, 2017-$14.11M–

More Solid Biosciences figures

See a number that looks wrong?